Skip to main navigation Skip to search Skip to main content

Interplay between CD28 and PD-1 in T cell immunotherapy

  • Zuhayr Jafri
  • , Jingwen Zhang
  • , Connor H. O'Meara
  • , Anthony M. Joshua
  • , Christopher R. Parish
  • , Levon M. Khachigian*
  • *Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

6 Citations (SciVal)

Abstract

Immune checkpoint therapy targeting the PD-1/PD-L1 axis has revolutionised the treatment of solid tumors. However, T cell exhaustion underpins resistance to current anti-PD-1 therapies, resulting in lower response rates in cancer patients. CD28 is a T cell costimulatory receptor that can influence the PD-1 signalling pathway (and vice versa). CD28 signalling has the potential to counter T cell exhaustion by serving as a potential complementary response to traditional anti-PD-1 therapies. Here we discuss the interplay between PD-1 and CD28 in T cell immunotherapy and additionally how CD28 transcriptionally modulates T cell exhaustion. We also consider clinical attempts at targeting CD28; the challenges faced by past attempts and recent promising developments.

Original languageEnglish
Article number107461
Number of pages10
JournalVascular Pharmacology
Volume158
DOIs
Publication statusPublished - Mar 2025

Fingerprint

Dive into the research topics of 'Interplay between CD28 and PD-1 in T cell immunotherapy'. Together they form a unique fingerprint.

Cite this